Pheochromocytoma Treatment

What Is Pheochromocytoma?

Pheochromocytoma is a rare tumor that develops in the adrenal medulla, the inner core of one of the two small adrenal glands that sit above your kidneys. The tumour produces excess catecholamines — stress hormones such as adrenaline and noradrenaline — and releases them in unpredictable surges that can push blood pressure and heart rate to dangerous levels. Treatment is usually surgical removal of the affected gland, but only after a period of medication has blunted the hormone effects enough to make anaesthesia and surgery safe.

Your adrenal glands normally release catecholamines in short, controlled bursts. When you face a genuine threat, these hormones raise your pulse, tighten your blood vessels and sharpen your attention — the familiar fight-or-flight response. A pheochromocytoma bypasses that control system. It can release large amounts of hormone without any trigger at all, or in response to something as ordinary as bending over, exercising or having an anaesthetic. The body reacts as if it were in extreme danger, again and again, even when nothing is wrong.

People arrive at this diagnosis by two main routes. Some have spent months or years with unexplained symptoms — sudden spikes in blood pressure, pounding headaches, a racing heartbeat, sweating, tremor, anxiety-like episodes, or a persistent feeling that something is wrong while routine tests keep coming back normal. Others discover an adrenal mass incidentally during a scan performed for an unrelated reason, and the uncertainty that follows can be just as unsettling as symptoms would be.

The condition is often treatable, but it must be approached in the right order. Operating on a pheochromocytoma before hormone levels and blood pressure are properly controlled carries real risk, which is why preparation is treated as part of the operation, not a formality before it. This page explains what the tumour is, how it announces itself, how it is confirmed, and what treatment and recovery actually involve.

Is pheochromocytoma cancer?

Most pheochromocytomas behave in a benign way, but the distinction between benign and malignant is less clear-cut here than in many other tumours. Pathologists cannot reliably predict a pheochromocytoma’s future behaviour from its appearance under the microscope alone. In practice, a pheochromocytoma is considered malignant only when it has spread to sites where this type of tissue does not normally exist — such as bone, liver, lungs or lymph nodes. A small proportion of tumours do spread in this way. Because behaviour cannot be fully predicted at the time of surgery, follow-up testing continues even after an apparently complete removal. That ongoing surveillance is not a sign that something has gone wrong; it is a standard part of managing a tumour whose long-term course reveals itself over time.

What causes pheochromocytomas?

Most pheochromocytomas arise sporadically, with no identifiable external cause — they are not linked to diet, lifestyle, smoking or psychological stress, and nothing a patient did or failed to do brings one on. A substantial minority, however, are connected to inherited gene changes. The best-known associations are multiple endocrine neoplasia type 2, von Hippel-Lindau disease, neurofibromatosis type 1, and variants in the succinate dehydrogenase (SDH) gene family. Hereditary tumours tend to appear at a younger age and are more likely to be bilateral, to arise outside the adrenal glands, or to recur. This is why genetic counselling and testing are often discussed after diagnosis — the result can change the surgical plan, the intensity of follow-up, and whether family members should be offered screening.

What is a paraganglioma?

A paraganglioma tumor is a closely related growth that develops outside the adrenal glands, arising from the same family of hormone-producing cells. A paraganglioma can form along nerve pathways in the chest, abdomen, pelvis, head or neck. Those in the abdomen and pelvis often secrete catecholamines and behave much like adrenal pheochromocytomas; those in the head and neck frequently do not produce significant hormone at all. The diagnostic and treatment principles overlap heavily, but the location changes the surgical approach and sometimes the specialists involved. Extra-adrenal disease also carries a stronger association with hereditary gene variants, which adds weight to the case for genetic testing when a paraganglioma is found.

Pheochromocytoma Symptoms

Pheochromocytoma symptoms are driven by hormone surges, so they often arrive in episodes rather than as a constant state. An attack may last minutes to an hour, begin abruptly and end just as abruptly. Between episodes, many patients feel entirely normal — one of the main reasons this diagnosis is so often delayed. Others have no distinct attacks at all, only blood pressure that stays stubbornly high despite treatment.

What are the signs and symptoms of a pheochromocytoma?

The classic pattern is episodic headache, heavy sweating and palpitations, usually accompanied by high blood pressure. Not every patient has this triad. Some have persistent hypertension with no discrete attacks, some have dramatic episodes with normal readings in between, and a few have surprisingly little to report despite significant hormone production. Other symptoms that appear in varying combinations include:

• Rapid or forceful heartbeat and chest discomfort
• Shortness of breath during episodes
• Tremor of the hands
• Flushing, or more often striking paleness
• Nausea and abdominal discomfort
• Unintended weight loss
• Constipation
• Weakness and fatigue after attacks
• Heat intolerance
• Panic-like episodes with a sense of dread

Episodes may be triggered by physical exertion, emotional stress, surgery, anaesthesia, certain medications, pressure on the abdomen, childbirth, trauma or even a change in posture. In some patients blood pressure swings dramatically between very high and near-normal; in others it remains consistently elevated and resists standard blood pressure medications. Both patterns deserve investigation.

What are the symptoms of an adrenal gland tumor?

Symptoms of an adrenal gland tumor depend on which hormone, if any, the tumour produces. A cortisol-producing tumour tends to cause weight gain, skin changes, muscle weakness and blood sugar problems. An aldosterone-producing tumour typically causes high blood pressure with low potassium. A catecholamine-producing tumour — a pheochromocytoma — produces the surge pattern described above. Many adrenal masses produce no hormone at all and cause no symptoms; they are discovered incidentally on scans done for other reasons. This variety is exactly why every adrenal mass should be hormonally evaluated before any decision is made about it — the treatment pathway differs completely depending on what the tissue is doing.

What are the psychiatric symptoms of pheochromocytoma?

Pheochromocytoma can produce sudden attacks of intense anxiety, panic, tremor, sweating and an overwhelming sense that something is badly wrong. These episodes can be indistinguishable from panic attacks, and it is not unusual for patients to be treated for an anxiety disorder for years before the tumour is found. The overlap is not a coincidence: adrenaline is the same hormone the body releases during genuine fear, so a surge from the tumour reproduces fear’s physical and emotional signature. Features that sometimes point away from a purely psychological explanation include attacks that arrive with no emotional trigger whatsoever, measurable blood pressure spikes during episodes, marked paleness rather than flushing, and headaches or sweating out of proportion to the anxiety itself. Endocrine evaluation can settle the question either way.

Pheochromocytoma Diagnosis

Pheochromocytoma diagnosis answers two questions in strict sequence: is the body producing excess catecholamines, and if so, where is the source? Getting the order right matters. Imaging without biochemical confirmation can mislead, because harmless adrenal nodules are common. And putting a needle into an unrecognised pheochromocytoma is dangerous — which is why biochemistry always comes first.

How is pheochromocytoma diagnosed?

Diagnosis begins with blood or urine tests that measure metanephrines and normetanephrines, the breakdown products of adrenaline and noradrenaline. These metabolites are produced continuously by the tumour, even between attacks, which makes them more reliable than trying to catch a hormone surge in the act. The tests are sensitive when collected and interpreted correctly, but results can be distorted by certain medications, acute stress, illness and the conditions under which the sample is taken. Borderline results are usually repeated under controlled conditions rather than acted on immediately, and endocrinology input is important whenever the numbers and the clinical picture do not obviously agree. If you want to understand how laboratory markers of this kind are drawn and read in practice, our guide to tumour marker blood tests explains the process step by step.

Once hormone excess is suspected or confirmed, cross-sectional imaging locates the tumour and characterises it. CT defines the size and side of the mass, its relationship to the kidney, major blood vessels, pancreas, liver and spleen, and the anatomy the surgeon will encounter. MRI may be preferred for younger patients, during pregnancy, when radiation exposure should be minimised, or when specific tissue features need clarification. The imaging is not only about finding the tumour — it shapes the choice between minimally invasive and open surgery.

Functional imaging with nuclear medicine techniques may be added when there is concern about multifocal, hereditary, recurrent or metastatic disease. These scans evaluate the biochemical behaviour of the tissue rather than just its shape: they can confirm that disease is confined to one adrenal gland, reveal deposits elsewhere in the body, and in metastatic disease help determine whether radionuclide-based therapy is a realistic option.

One point deserves emphasis because it protects patients from harm: an adrenal mass should not be biopsied before its hormonal status is known. Needle biopsy of an undiagnosed pheochromocytoma can provoke a severe hormone crisis, and it rarely provides information that the blood tests and imaging cannot. Biopsy is generally avoided unless very specific conditions are met and a specialist team has judged it necessary.

Genetic counselling and testing complete the diagnostic picture for many patients. Testing is particularly relevant for those diagnosed at a young age, those with bilateral or extra-adrenal tumours, recurrent disease, a family history of related conditions, or certain biochemical and imaging patterns. A positive result can change the operation itself — for example, by making adrenal-sparing surgery worth discussing — and it defines how intensively the patient, and potentially their relatives, should be monitored in the years ahead.

Pheochromocytoma Treatment

Pheochromocytoma treatment has two arms that cannot be separated: controlling the effects of the excess hormones, and removing their source. Surgery is the main treatment for localised disease, but scheduling the operation is the second step, not the first. Because the tumour can release powerful stress hormones at any moment — including in response to the operation itself — the body must be prepared before anyone operates.

Patients with a functioning pheochromocytoma usually receive alpha-adrenergic blockade for a period before surgery. This class of medication relaxes blood vessels and dampens the pressure surges the tumour can cause. The treating team adjusts the dose gradually, guided by blood pressure, heart rate, symptoms and side effects such as dizziness on standing. As the blood vessels relax, blood volume often needs to be restored, so some patients are given guidance on salt and fluid intake — always individualised, and adjusted for anyone with heart, kidney or vascular disease.

If the heart rate remains high after alpha-blockade has taken effect, the team may add a beta-blocker. The sequence is deliberate: in pheochromocytoma, beta-blockade given before adequate alpha-blockade can paradoxically worsen blood pressure, because it removes one safety valve while the vessels are still clamped down by the tumour’s hormones. This is precisely the kind of decision that belongs to the treating physicians, made with the full biochemical picture in front of them, and never adjusted independently.

When disease is metastatic, recurrent or not suitable for immediate surgery, the strategy broadens. Options can include medication to control hormone symptoms over the long term, targeted nuclear medicine (radionuclide) therapies, systemic drug therapy, local treatments directed at specific lesions, and surgery as one component of a wider disease-control plan. In this setting the goal shifts from complete removal to durable control of the disease and its hormone effects. Which combination fits depends on tumour biology, genetic findings, imaging results, symptoms and the patient’s overall condition — these tumours vary widely in behaviour, and the plan must vary with them.

Who May Need Pheochromocytoma Treatment?

Evaluation and treatment are warranted when symptoms suggest excess catecholamine release, or when imaging shows an adrenal mass and biochemical testing confirms hormone production. The classic presentation — episodic headache, sweating and palpitations with high blood pressure — is one route in, but so is hypertension that resists standard medication, especially in a younger patient or one whose readings swing unpredictably. Some patients have frequent dramatic attacks; others have persistent, quiet hormone excess doing gradual damage in the background.

A second group reaches treatment through an adrenal incidentaloma: a mass found on a scan performed for an entirely different reason. When subsequent hormone testing shows catecholamine secretion, the mass is treated as a pheochromocytoma regardless of how little it has announced itself. This pathway is one reason hormonal evaluation of every adrenal mass matters — it determines what can safely be done next.

A third group is identified after a crisis: severe blood pressure instability during an operation, childbirth, trauma care or an acute illness that prompts a search for the cause. Finally, some patients are evaluated because of a known family history of hereditary tumour syndromes, before any symptoms appear at all. In these families, planned surveillance can find tumours when they are small and most straightforward to treat.

Conditions and Indications Addressed by Treatment

The primary indication is a biochemically confirmed catecholamine-producing adrenal tumour. Treatment is also considered for strongly suspected pheochromocytoma when imaging and the clinical picture support the diagnosis, even if the biochemistry needs careful repetition or specialist interpretation before it is definitive.

The full range of situations a specialist team manages includes: a single adrenal pheochromocytoma; bilateral adrenal pheochromocytomas; recurrent disease after previous surgery; hereditary pheochromocytoma within a genetic syndrome; tumours discovered during the investigation of resistant hypertension; and paragangliomas that behave like catecholamine-producing tumours, whose location may change the surgical plan considerably.

In some patients, pheochromocytoma is one part of a broader inherited condition. Multiple endocrine neoplasia type 2 links it with thyroid and parathyroid disease. Von Hippel-Lindau disease can also cause kidney tumours, pancreatic lesions and certain brain and spinal cord tumours. Neurofibromatosis type 1 and SDH gene variants each carry their own associated risks. When hereditary disease is possible, the treatment plan has to look beyond the current tumour: long-term surveillance, the risk of tumours on both sides or at multiple sites, the case for preserving adrenal tissue where oncologically safe, and counselling for family members all belong in the discussion.

For patients with metastatic pheochromocytoma or paraganglioma, management usually involves several specialties working from a shared plan. Surgery for selected tumours, medication to control hormone effects, radiotherapy or nuclear medicine approaches, systemic therapy and structured monitoring can all play a role. The emphasis falls on long-term disease control, symptom reduction and the prevention of complications, with the mix of treatments revisited as the disease evolves.

How Pheochromocytoma Surgery Is Performed

At an experienced centre, treatment is a coordinated pathway rather than a single appointment. The endocrinologist reviews symptoms, blood pressure patterns, current medications, prior test results and family history, repeating laboratory work where needed. Radiologists familiar with adrenal disease review the imaging. Surgeons weigh minimally invasive against open approaches. Anaesthesia physicians assess cardiovascular risk and plan specifically for the blood pressure swings this operation can produce. Each specialty’s assessment feeds the others.

Cardiac evaluation is often part of preparation, because long-standing catecholamine excess can strain the heart — sometimes causing rhythm disturbances, a weakened heart muscle, or stress on the blood vessels. Electrocardiography, echocardiography or a fuller cardiology assessment may be arranged depending on symptoms and history. The anaesthesia team also reviews medications, allergies, airway considerations and any previous experiences with anaesthesia, so that nothing about the patient’s physiology comes as a surprise on the day.

Imaging drives the surgical plan. CT and MRI define the mass, its blood supply and its neighbours — kidney, major vessels, pancreas, liver, spleen. Functional imaging, when used, confirms whether disease is limited to one adrenal gland. Together these studies determine the incision strategy, anticipate where vascular control will be needed, and reduce the chance of unexpected findings once the operation is under way.

On the day of surgery, the sequence typically runs as follows:

1. Monitoring is established, usually including an arterial line that tracks blood pressure beat by beat, so the team can respond within seconds rather than minutes.
2. Anaesthesia is induced according to a plan built around the surge risk, with short-acting blood pressure medications drawn up and ready.
3. Access is created — small laparoscopic ports for a minimally invasive operation, or a formal incision for open surgery.
4. The surgeon dissects towards the adrenal gland with deliberately minimal handling of the tumour, because manipulation itself can trigger hormone release.
5. Where feasible, the adrenal vein is identified and controlled early, cutting off the route by which hormone surges enter the circulation.
6. The gland is separated from surrounding tissue and removed intact, in a protective manner, then sent to pathology.
7. After removal, blood pressure can swing the other way and drop; the team is prepared with fluids and rapid-acting medications for this transition too.
8. The incisions are closed and the patient moves to a closely monitored recovery area.

In a minimally invasive adrenalectomy, the surgeon works through small incisions with a camera and fine instruments, approaching either through the abdomen or from the back, depending on the tumour’s position and the patient’s anatomy and surgical history. This approach usually means less post-operative discomfort and a shorter hospital stay, and it suits many localised adrenal tumours well.

Open surgery is recommended when the tumour is large, when imaging raises the possibility of invasion into neighbouring structures, when malignancy is suspected, or when previous operations or unusual anatomy make the minimally invasive route less safe. An open approach gives the surgeon direct exposure and control of major vessels and adjacent organs. Recovery is usually longer, but for complex disease the open operation is often the safer and more complete choice — the best approach is never simply the smallest incision.

Partial adrenalectomy — removing the tumour while preserving part of the gland — may be considered for selected patients, particularly those with bilateral tumours or a hereditary risk of developing more. The trade-off requires careful judgement. Preserving tissue protects hormone function, but removing too little may raise the risk of recurrence; removing both adrenal glands entirely means lifelong adrenal insufficiency, with steroid replacement therapy and a plan for managing illness and emergencies. For patients facing bilateral disease, this discussion is one of the most important of the entire pathway.

Operating time varies: a straightforward minimally invasive adrenalectomy may take a few hours, while bilateral, recurrent or open operations take longer. Afterwards, patients are monitored closely — some briefly in a high-dependency or intensive care setting — for low blood pressure, low blood sugar, pain, bleeding and adrenal hormone needs. Blood sugar deserves particular attention, because catecholamine excess affects glucose metabolism and levels can shift once the tumour is out. Blood pressure often improves after surgery, but the pattern differs between patients: some can reduce or stop antihypertensive medication under their doctor’s supervision, while others still need treatment because they also have essential hypertension or vascular changes from years of hormone exposure.

Pathology examination confirms the diagnosis and looks for features associated with higher-risk behaviour. As explained earlier, microscopy alone cannot settle the benign-versus-malignant question for this tumour, which is why the pathology report is read alongside the biochemistry, imaging and genetics — and why follow-up testing continues after even an apparently complete removal.

Before discharge, recovery planning covers wound care, a gradual return to activity, home blood pressure monitoring, medication review and the schedule for follow-up biochemical testing. Discharge documentation includes a summary for the physician continuing the patient’s care, covering the operation performed, the pathology findings, medication changes and the recommended surveillance plan.

Why Acting Early Matters

Pheochromocytoma is unpredictable. Some patients live with intermittent symptoms for years; others experience a sudden hypertensive crisis with little warning. Delaying evaluation leaves the cardiovascular system exposed to repeated hormone surges, which over time raise the risk of serious events — stroke, heart attack, heart failure, dangerous rhythm disturbances, aortic complications and kidney injury. Even symptoms that seem to come and go can conceal steady, cumulative strain.

Timely diagnosis also prevents unsafe interventions. An adrenal mass whose hormonal status is unknown should never be biopsied casually, and any operation — for any condition — is safer when the surgical and anaesthesia teams know a catecholamine-producing tumour may be present. Undiagnosed pheochromocytomas have caused severe blood pressure instability during unrelated surgery, childbirth, trauma care and invasive procedures precisely because nobody knew to prepare for them.

Early treatment also keeps the surgical options open. Smaller, localised tumours are generally better suited to minimally invasive removal than large or invasive masses. In hereditary cases, early recognition allows screening for other tumours and gives family members the chance to seek genetic counselling on their own timetable. And for patients whose disease has already spread, earlier specialist evaluation means earlier symptom control and a clearer long-term strategy.

Benefits of Pheochromocytoma Treatment

What treatment can realistically achieve depends on tumour behaviour, overall health and the completeness of removal, but the central aims are consistent: reduce the hormone-driven risk and restore safer, more stable cardiovascular control.

Benefit	What It Means for You
Control of excess hormone release	Removing a functioning tumour can reduce or eliminate catecholamine surges that cause headaches, palpitations, sweating and sudden blood pressure spikes.
Improved blood pressure stability	Many patients experience better blood pressure control after treatment, although some may still need medication for underlying hypertension.
Reduced risk of cardiovascular crises	Appropriate preparation and tumour removal can lower the risk of severe complications related to uncontrolled hormone release.
Clearer diagnosis and risk assessment	Surgical pathology, imaging and biochemical follow-up help determine whether additional monitoring or treatment is needed.
Opportunity for genetic and family guidance	When hereditary disease is suspected, testing and counselling can guide long-term surveillance for the patient and potentially affected relatives.

Recovery Timeline After Pheochromocytoma Surgery

Recovery depends on the surgical approach, the complexity of the tumour, how much the hormones affected the body before surgery, and the patient’s general condition. Most people follow a broadly similar pattern: closely monitored early recovery, then a gradual return to normal activity.

Time Period	What Patients Can Expect
Day 1	Close monitoring of blood pressure, heart rate, fluids, pain control and blood sugar. Some patients spend time in a higher-acuity unit depending on their risk profile.
First Week	Gradual walking, diet advancement, medication adjustment and preparation for discharge. Minimally invasive surgery usually allows a shorter hospital stay than open surgery.
First Month	Energy improves gradually. Patients monitor blood pressure, avoid heavy lifting as instructed and attend follow-up to review pathology and medication needs.
Longer Term	Biochemical testing and imaging when indicated help detect recurrence or persistent disease. Genetic counselling may be part of ongoing care for selected patients.

Factors That Influence Outcomes

A good result in pheochromocytoma care rests on several connected factors, and the first is accurate diagnosis. Because the symptoms can resemble anxiety disorders, panic attacks, thyroid disease, heart rhythm disorders or ordinary hypertension, careful endocrine evaluation matters. Properly collected biochemical tests, interpreted by clinicians who see this condition regularly, reduce the risk of a missed or mistaken diagnosis — in either direction.

The second factor is the quality of preoperative preparation. Patients who reach the operating theatre with well-controlled blood pressure and heart rate are better positioned for safe anaesthesia and a smoother recovery. Medication selection, dosing, timing and monitoring all demand experience, particularly for patients with heart disease, kidney disease, pregnancy, advanced age, severe hypertension or previous adverse reactions to medication.

Tumour characteristics come third. Size, location, whether the tumour is confined to the adrenal gland, whether there are multiple tumours, and whether imaging suggests invasion all shape the surgical approach and its risks. A small, well-localised adrenal tumour is treated very differently from a large mass wrapped around major blood vessels, or a recurrence in a previously operated field.

The surgeon’s specific experience with adrenal disease matters as well. This operation demands gentle handling of the tumour, early vascular control where feasible, and continuous coordination with the anaesthesia team through the moments when blood pressure can change fastest. The right approach for a given patient is the one that allows safe and complete treatment of that patient’s anatomy and disease — which is not always the least invasive one.

Anaesthesia expertise deserves its own mention, because pheochromocytoma operations are physiologically unlike most abdominal surgery. The anaesthesia team must be ready for sharp blood pressure rises during induction and tumour manipulation, then a possible fall once the tumour is out — and must manage both transitions in real time with continuous monitoring and immediate access to the right short-acting medications.

Genetics can influence both the operation and everything after it. Hereditary syndromes raise the likelihood of bilateral, recurrent or multifocal disease, which changes the calculus on adrenal-sparing surgery and dictates a more intensive surveillance schedule. Genetic findings can also steer the choice of imaging over the years that follow.

Finally, long-term follow-up shapes outcomes as much as the surgery itself. Even after apparently complete removal, biochemical monitoring is needed because recurrence or new tumours can develop, particularly in hereditary or extra-adrenal disease. Patients do best when they leave hospital knowing what their surveillance schedule looks like, which records to keep, and how their local physicians will receive the information they need to continue care.

How Acibadem Coordinates Pheochromocytoma Care

At Acibadem, care for pheochromocytoma is coordinated among endocrinology, endocrine or urologic surgery, anaesthesia, radiology, nuclear medicine, cardiology when needed, and pathology. The goal is specific: confirm the diagnosis, stabilise the hormone-related risks, remove the tumour safely when appropriate, and build a follow-up plan around the biology of the individual disease.

Complex cases — hereditary disease, bilateral tumours, recurrence after previous surgery, ambiguous imaging or possible metastatic spread — may be reviewed in multidisciplinary discussions, so that diagnostic findings, operative options and follow-up needs are weighed together rather than in sequence by separate departments. For a rare tumour where the details matter this much, that shared review reduces fragmented decision-making.

Technology is used where it answers clinical questions: Is the tumour producing hormone? Is disease limited to one gland? Is minimally invasive surgery appropriate? Is there evidence of disease elsewhere, and what surveillance does that imply? Laboratory evaluation, cross-sectional and functional imaging, perioperative monitoring and pathology each address one of these questions. Our guide to how technology supports diagnosis and treatment at Acibadem describes this in more detail.

Second opinions are common in this condition, and for understandable reasons: biochemical results can be borderline, imaging can be ambiguous, surgery is sometimes proposed without adequate hormone preparation, and patients are occasionally told a tumour is too complex for minimally invasive removal when an adrenal-focused team might judge otherwise. A structured review of the laboratory results, imaging and medication history can clarify both the diagnosis and the safest next step.

Life After Pheochromocytoma Treatment

When one adrenal gland is removed and the other is healthy, the remaining gland usually takes over hormone production, and most patients do not need hormone replacement. When both glands are removed — sometimes unavoidable in bilateral disease — lifelong steroid replacement is required, managed by an endocrinologist, together with a clear plan for illness and emergencies. Patients facing this scenario should have it explained thoroughly before surgery, not discovered afterwards.

Long-term follow-up centres on periodic biochemical testing, with imaging added when the results or the patient’s risk profile call for it. The intensity of surveillance depends on genetics, tumour features and whether disease was confined to one gland. Keeping copies of the operation note, pathology report and each round of test results makes this follow-up far easier, whoever continues the care and wherever it happens.

Pheochromocytoma is rare, but the pathway through it is well understood: careful biochemical confirmation, unhurried preparation, an operation planned around the tumour’s physiology, and follow-up matched to the biology of the disease. Treatment succeeds not by moving fast, but by doing each of those steps in the right order — and that is a plan a well-coordinated team can lay out clearly from the first review of your results.